EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions

Federico Pravisano, Jacopo Costa, Lorenzo De Marchi iD, Gaetano Pascoletti, Elena Poletto, Michele Del Vecchio iD, Andrea Spagnoletti iD, Carolina Cimminiello, Nikolaos Papadopoulos, Jacopo Pigozzo iD, Luisa Piccin iD, Gabriele Roccuzzo iD und 4 weitere

Cancers · 01.06.2026 · 18 (11) · 1802

DOI: 10.3390/cancers18111802 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 01.06.2026. Verfasst von Federico Pravisano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Santa Maria della Misericordia Academic Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udin…. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of adjuvant therapy in stage III melanoma is well established in clinical practice. Because stage IIB–IIC melanoma carries a risk of recurrence and melanoma-specific mortality comparable to that of stage III disease, adjuvant approaches have also been developed for patients with thick stage II tumors. Both pembrolizumab and nivolumab have demonstrated efficacy in reducing the risk of local and distant recurrence in patients with high-risk stage II melanoma, whereas evidence supporting the use of BRAF-MEK inhibitors in this setting remains inconclusive. Combinations of immune checkpoint inhibitors, as well as immunotherapy combined with mRNA-based vaccines, are currently under investigation in clinical trials. However, given the non-trivial risk of immune-related adverse events, careful selection of patients with stage II disease who are most likely to derive meaningful benefit from adjuvant therapy is essential. In this context, several clinicopathologic variables and gene expression profiling-based prognostic tools have been proposed to refine risk stratification. To date, however, none of these instruments have been incorporated into routine clinical practice, and no validated predictive biomarkers are available. Accordingly, optimal patient selection for adjuvant therapy remains an important unmet clinical need in early-stage melanoma.

Schlagwörter

Stichwörter der Autor:innen

adjuvant therapyanti-PD-1 therapycirculating tumor DNAcutaneous melanomagene expression profilingimmune checkpoint inhibitorsprognostic biomarkersrecurrence-free survivalstage II melanoma

Autor:innen und Institutionen

  • Department of Medical Oncology, Santa Maria della Misericordia Academic Hospital, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy.
  • Department of Medical Oncology, AULSS4 Veneto Orientale, Portogruaro Hospital, 30036 Portogruaro, Italy.
  • Department of Medicine (DMED), University of Udine, 33100 Udine, Italy.
  • Unit of Melanoma Medical Oncology, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.
  • Melanoma Unit, Division of Clinical and Experimental Oncology and Immunotherapy of Melanoma, European Institute of Oncology, 20141 Milan, Italy.
  • Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.

ORCID-Profile: Lorenzo De Marchi, Michele Del Vecchio, Andrea Spagnoletti, Jacopo Pigozzo, Luisa Piccin, Gabriele Roccuzzo, Paolo Fava, Fabio Puglisi, Alessandro Marco Minisini

Zitieren

APA

Pravisano, F., Costa, J., Marchi, L., Pascoletti, G., Poletto, E., Del Vecchio, M., Spagnoletti, A., Cimminiello, C., Papadopoulos, N., Pigozzo, J., Piccin, L., Roccuzzo, G., Fava, P., Puglisi, F., Aprile, G., & Minisini, A. M. (2026). Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions. Cancers, 18(11), 1802. https://doi.org/10.3390/cancers18111802

Vancouver

Pravisano F, Costa J, Marchi L, Pascoletti G, Poletto E, Del Vecchio M, et al. Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions. Cancers. 2026;18(11):1802. doi:10.3390/cancers18111802

BibTeX
@article{Pravisano2026,
  author = {Pravisano, Federico and Costa, Jacopo and Marchi, Lorenzo De and Pascoletti, Gaetano and Poletto, Elena and Del Vecchio, Michele and Spagnoletti, Andrea and Cimminiello, Carolina and Papadopoulos, Nikolaos and Pigozzo, Jacopo and Piccin, Luisa and Roccuzzo, Gabriele and Fava, Paolo and Puglisi, Fabio and Aprile, Giuseppe and Minisini, Alessandro Marco},
  title = {Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future Directions},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {1802},
  doi = {10.3390/cancers18111802}
}
Kostenlos starten →